Scientific recommendation on classification of advanced therapy medicinal products


Disclaimer: This document is a summary for public release of a scientific recommendation on classification of advanced therapy medicinal products. The original text adopted by the Committee for Advanced Therapies (CAT) has been redacted to delete commercially confidential information.

The present scientific recommendation refers exclusively to the case as presented to the European Medicines Agency (EMA) without prejudice to future evaluations by the Agency.

It is stressed that the scientific recommendation on advanced therapy classification does not amount to any endorsement of the plausibility of the product, including the mode of action or therapeutic indication(s) claimed by the applicant.

Brief description (or name when available) of the active substance(s)

Allogeneic haptenized, stimulated and irradiated non-proliferative colorectal tumour whole cells derived from 3 colorectal cell lines.

Brief description of the finished product

Cells suspension composed of allogeneic stimulated haptenized and irradiated non-proliferative colorectal tumour whole cells derived from 3 colorectal cancer cell lines.

Proposed indication

Treatment of colorectal cancer.

EMA/CAT conclusion

The procedure was finalised on 12 May 2017 for the following recommendation.

On the basis that the product:

Allogeneic haptenized, stimulated and irradiated non-proliferative colorectal tumour whole cells derived from 3 colorectal cell lines.

Cells suspension composed of allogeneic stimulated haptenized and irradiated non-proliferative colorectal tumour whole cells derived from 3 colorectal cancer cell lines.

Treatment of colorectal cancer.
• is presented as having properties for treating a disease through the immunological action of its cells;

• contains cells that have been subject to substantial manipulation so that biological characteristics, physiological functions or structural properties relevant for the intended clinical use have been altered,

the EMA/CAT considers that the Product falls within the definition of a somatic cell therapy medicinal product as provided in Article 2(1) of Regulation (EC) 1394/2007.